News Column

Sorrento Therapeutics Adds Daniel Levitt as Board Director

February 15, 2014

Sorrento Therapeutics, a late-stage clinical oncology company, announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors.

Dr. Levitt currently serves as Executive Vice President and Chief Medical Officer of CytRx Corp.

"Daniel's proven expertise overseeing the successful development of major oncology drugs will be invaluable to Sorrento as we advance our pipeline to address the unmet needs of cancer patients," said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento.

Dr. Levitt brings more than 28 years of senior management experience, spearheading numerous oncology drug development programs to commercialization at leading biotechnology and pharmaceutical companies, including CytRx Corp., Cerimon Pharmaceuticals, Dynavax Technologies Corp., Affymax, Protein Design Labs, Geron, Sandoz Pharmaceuticals, and Hoffmann-LaRoche. Dr. Levitt has received 10 research awards and authored or co-authored more than 200 papers and abstracts.

In addition, Sorrento announced that Ernst-Guenter Afting, Ph.D. has stepped down from the Board of Sorrento to focus on consulting and board activities in Europe. "We thank Dr. Afting for his many contributions to the Company," said Henry Ji.

More Information:

www.sorrentotherapeutics.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Professional Services Close - Up


Story Tools